参考文献/References:
[1] 骆 巧,李 刚.自身免疫性肝病药物治疗研究进展[J].陕西医学杂志,2022,51(10):1318-1321.
[2] Richardson N,Wootton GE,Bozward AG,et al.Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease[J].Semin Immunopathol,2022,44(4):461-474.
[3] Wang CR,Tsai HW.Autoimmune liver diseases in systemic rheumatic diseases[J].World J Gastroenterol,2022,28(23):2527-2545.
[4] Taniki N,Nakamoto N,Chu PS,et al.Th17 cells in the liver:Balancing autoimmunity and pathogen defense[J].Semin Immunopathol,2022,44(4):509-526.
[5] 陈双平,张 澄,谢海波,等.聚肌胞苷酸加重三氯乙烯致敏小鼠免疫性肝损伤中IL-23和IL-17表达[J].中国职业医学,2019,46(1):8-14.
[6] Cai T,Xu L,Xia D,et al.Polyguanine alleviated autoimmune hepatitis through regulation of macrophage receptor with collagenous structure and TLR4-TRIF-NF-κB signalling[J].J Cell Mol Med,2022,26(22):5690-5701.
[7] Yu Q,Cheng P,Wu J,et al.PPARγ/NF-κB and TGF-β1/Smad pathway are involved in the anti-fibrotic effects of levo-tetrahydropalmatine on liver fibrosis[J].J Cell Mol Med,2021,25(3):1645-1660.
[8] Jefferson B,Ali M,Grant S,et al.Thrombospondin-1 exacerbates acute liver failure and hepatic encephalopathy pathology in mice by activating transforming growth factor β1[J].Am J Pathol,2020,190(2):347-357.
[9] 王绮夏,蒋 翔,连 敏,等.2015年欧洲肝病学会临床实践指南:自身免疫性肝炎[J]..临床肝胆病杂志,2015,31(12):2000-2019.
[10] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J].临床肝胆病杂志,2015,31(12):1980-1988.
[11] European Association for the Study of the Liver.EASL clinical practice guidelines:Management of cholestatic liver diseases[J].J Hepatol,2009,51(2):237-267.
[12] 马 雄,王绮夏.自身免疫性肝病的研究现状[J].中华传染病杂志,2020,38(8):465-467.
[13] Sarcognato S,Sacchi D,Grillo F,et al.Autoimmune biliary diseases:Primary biliary cholangitis and primary sclerosing cholangitis[J].Pathologica,2021,113(3):170-184.
[14] Gu D,Zhang M,Wang Y,et al.Causal effect of autoimmune liver diseases on cancer:Meta-analyses of cohort studies and Mendelian randomization study[J].Liver Int,2022,42(10):2216-2226.
[15] Trivedi PJ,Hirschfield GM.Recent advances in clinical practice:Epidemiology of autoimmune liver diseases[J].Gut,2021,70(10):1989-2003.
[16] Cazzagon N,Floreani A.Primary biliary cholangitis:Treatment[J].Curr Opin Gastroenterol,2021,37(2):99-104.
[17] Jiang Y,Xu BH,Rodgers B,et al.Characteristics and inpatient outcomes of primary biliary cholangitis and autoimmune hepatitis overlap syndrome[J].Clin Transl Hepatol,2021,9(3):392-398.
[18] Absolonová K,Matucha P,terzl I.Th1,Th2 and Th17 lymphocytes in autoimmune thyreopathies[J].Vnitr Lek,2021,67(8):23-28.
[19] Beringer A,Miossec P.IL-17 and IL-17-producing cells and liver diseases,with focus on autoimmune liver diseases[J].Autoimmun Rev,2018,17(12):1176-1185.
[20] 曲 畅,吴云红,穆靖洲,等.核转录因子-κB在缺氧导致的炎症中的作用[J].生理科学进展,2018,49(1):39-43.
[21] 姚 婷,万 明.基于Akt/mTOR通路观察补中益气颗粒对实验性自身免疫性甲状腺炎大鼠的保护作用[J].陕西中医,2023,44(2):159-164.
[22] 王 波,李 志,陶 晶,等.自身免疫性肝病患者外周血 Th17与 Treg 细胞及其相关因子表达的研究[J].中国实验诊断学,2014,18(9):1443-1445.
[23] Kardashian A,Serper M,Terrault N,et al.Health disparities in chronic liver disease[J].Hepatology,2023,77(4):1382-1403.